Literature DB >> 6678302

Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).

N Savaraj, K Lu, L G Feun, M E Leavens, D Stewart, M A Burgess, R S Benjamin, T L Loo.   

Abstract

[14C]AZQ (2-4 mg/m2, 100-200 mCi) was administered at varying times to five patients undergoing surgical resection of intracerebral tumors. Plasma, cerebrospinal fluid (CSF), edematous brain, and tumor specimens were obtained during surgery and the concentration of AZQ was determined radiochemically and chromatographically. Total [14C]AZQ equivalent concentration in tumor for two patients was determined to be 47.5% and 85% of concurrent plasma concentration which was similar to that found in normal brain (60.4% and 75.5% respectively). Only 18-45% of the total radioactivity in tumor tissue and 30-56% in plasma were accounted for by unchanged AZQ. These findings suggest that AZQ may be metabolized to a certain extent. Tissue samples from various organs were obtained during autopsy in a patient who expired ten days after AZQ administration. The highest AZQ concentration was found in the liver, followed by the kidney. Comparable amounts were found in normal brain and brain tumor (22 ng/g vs. 31 ng/g respectively). These results indicate that AZQ penetrates readily into the normal brain and brain tumor with a tendency to persist.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6678302     DOI: 10.1007/bf00153636

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  9 in total

1.  Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system.

Authors:  L B Mellett
Journal:  Cancer Treat Rep       Date:  1977-07

2.  Osmotic opening of tight junctions in cerebral endothelium.

Authors:  M W Brightman; M Hori; S I Rapoport; T S Reese; E Westergaard
Journal:  J Comp Neurol       Date:  1973-12-15       Impact factor: 3.215

3.  The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier.

Authors:  V A Levin; H D Landahl; M A Freeman-Dove
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

4.  Potential central nervous system antitumor agents. Aziridinylbenzoquinones.

Authors:  F Chou; A H Khan; J S Driscoll
Journal:  J Med Chem       Date:  1976-11       Impact factor: 7.446

5.  Permeability characteristics of brain adjacent to tumors in rats.

Authors:  V A Levin; M Freeman-Dove; H D Landahl
Journal:  Arch Neurol       Date:  1975-12

6.  Potential CNS antitumor agents VI: aziridinylbenzoquinones III.

Authors:  J S Driscoll; L Dudeck; G Congleton; R I Geran
Journal:  J Pharm Sci       Date:  1979-02       Impact factor: 3.534

7.  2,5-Diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone I: Kinetics in aqueous solutions by high-performance liquid chromatography.

Authors:  G K Poochikian; J C Cradock
Journal:  J Pharm Sci       Date:  1981-02       Impact factor: 3.534

8.  Ability of a new antitumor agent, AZQ, to penetrate into cerebrospinal fluid.

Authors:  P E Gormley; J H Wood; D G Poplack
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

9.  2,5-Diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone II: Isolation and characterization of degradation products.

Authors:  G K Poochikian; J A Kelley
Journal:  J Pharm Sci       Date:  1981-02       Impact factor: 3.534

  9 in total
  20 in total

Review 1.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma.

Authors:  J Maral; M Poisson; B F Pertuiset; P Mashaly; M Weil; C Jacquillat; A J Grillo-Lopez
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

Review 3.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  The role of chemotherapy in the treatment of patients with brain metastases from solid tumors.

Authors:  J C Buckner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

5.  The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.

Authors:  L G Feun; N Savaraj; K Lu; Z Guo; L G Raulston; R S Benjamin; W S Fields; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

6.  Cisplatin plus cytosine arabinoside in adults with malignant gliomas.

Authors:  D J Stewart; M T Richard; B Benoit; H Hugenholtz; N Russell; J Dennery; E Peterson; Z Grahovac; G Belanger; S Aitkens
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

7.  A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.

Authors:  L G Feun; W K Yung; M E Leavens; M A Burgess; E A Obbens; A Y Bedikian; N Savaraj; D J Stewart; R S Benjamin; W S Fields
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

8.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J Dennery; D Nundy; J Prior; V Montpetit; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

10.  Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.

Authors:  D J Stewart; D Grewaal; M D Redmond; N Z Mikhael; V A Montpetit; R Goel; R M Green
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.